PAVING the way: Patient preferences to Assess Value IN Gene therapies KU Leuven
Drug development is increasingly focusing on precision medicine, Advanced Therapy Medicinal Products (ATMPs) including gene therapies, and orphan drugs. With the rise of gene therapies, that may have the potential to create permanent effects in patients, decision-making (on the level of marketing authorization, health technology assessment (HTA) and payer decision making, and shared-decision making between patients and physicians) will ...